PRESS RELEASE

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2021:

- Cash: € 316,759.75
- Number of shares: 100,139

- Number of executions on buy side on semester: 993
- Number of executions on sell side on semester: 636
- Traded volume on buy side on semester: 152,845 shares for € 1,470,441.72
- Traded volume on sell side on semester: 98,168 shares for € 1,025,659.18

At the last half-year report as of December 31, 2021, the following resources were available in the liquidity account:

- Cash: € 761,542.29
- Number of shares: 45,462

- Number of executions on buy side on semester: 1,253
- Number of executions on sell side on semester: 1,425
- Traded volume on buy side on semester: 209,935 shares for € 2,438,368.87
- Traded volume on sell side on semester: 211,076 shares for € 2,510,782.11

When the contract was initially implemented, the following resources were included in the liquidity account:

- Cash: € 163,510.42
- Number of shares: 34,063

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	**993**	**152,845**	**1,470,441.72**	**636**	**98,168**	**1,025,659.18**
03/01/2022	8	1,000	11,800.00	12	2,471	29,553.16
04/01/2022	33	4,501	53,336.85	11	2,000	24,160.00
05/01/2022	20	1,950	22,542.00	2	500	5,850.00
06/01/2022	3	49	563.50	-	-	-
07/01/2022	38	3,187	36,013.10	-	-	-
10/01/2022	30	3,999	43,709.07	-	-	-
11/01/2022	7	1,000	10,680.00	13	2,060	22,309.80
12/01/2022	12	2,000	22,160.00	9	3,440	38,872.00
13/01/2022	9	500	5,480.00	-	-	-
14/01/2022	5	1,500	16,380.00	21	1,614	17,931.54
17/01/2022	2	1,000	10,980.00	7	639	7,099.29
19/01/2022	3	222	2,442.00	-	-	-
20/01/2022	1	1	11.20	19	3,008	33,689.60
21/01/2022	8	1,234	13,771.44	6	203	2,285.78
24/01/2022	30	5,265	57,072.60	-	-	-
25/01/2022	1	1	10.54	-	-	-
26/01/2022	-	-	-	8	1,500	16,125.00
27/01/2022	3	1,000	10,680.00	5	500	5,400.00
28/01/2022	8	1,319	14,179.25	17	2,537	27,627.93
31/01/2022	15	1,932	20,614.44	9	2,000	21,560.00
01/02/2022	-	-	-	31	5,500	61,105.00
02/02/2022	-	-	-	8	1,000	11,800.00
03/02/2022	10	2,000	22,720.00	11	827	9,436.07
04/02/2022	4	501	5,691.36	24	1,565	17,966.20
07/02/2022	3	500	5,750.00	9	2,000	23,340.00
08/02/2022	3	501	5,811.60	17	3,000	35,580.00
09/02/2022	7	1,501	17,666.77	16	1,500	17,880.00
10/02/2022	-	-	-	1	50	598.00
11/02/2022	8	542	6,449.80	4	950	11,381.00
14/02/2022	27	4,852	56,380.24	-	-	-
15/02/2022	4	500	5,530.00	-	-	-
16/02/2022	4	500	5,550.00	3	501	5,641.26
17/02/2022	25	2,501	27,511.00	1	422	4,709.52
18/02/2022	4	1,000	10,860.00	12	2,185	23,947.60
21/02/2022	31	3,546	38,119.50	-	-	-
22/02/2022	23	3,648	37,428.48	5	755	7,776.50
23/02/2022	-	-	-	40	4,245	44,827.20
24/02/2022	31	5,306	53,272.24	2	155	1,612.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	**993**	**152,845**	**1,470,441.72**	**636**	**98,168**	**1,025,659.18**
25/02/2022	-	-	-	36	4,345	45,622.50
28/02/2022	4	500	5,250.00	7	3,500	38,360.00
01/03/2022	6	1,749	19,169.04	10	2,109	23,768.43
02/03/2022	16	2,548	27,696.76	-	-	-
03/03/2022	11	1,842	19,506.78	-	-	-
04/03/2022	16	2,058	21,403.20	-	-	-
07/03/2022	27	5,430	52,671.00	10	2,500	24,750.00
08/03/2022	5	1,501	14,964.97	8	2,501	25,760.30
09/03/2022	6	1,000	9,950.00	2	548	5,540.28
10/03/2022	-	-	-	3	500	5,050.00
11/03/2022	6	1,000	9,950.00	-	-	-
14/03/2022	4	1,500	15,060.00	6	500	5,050.00
15/03/2022	17	2,500	24,575.00	1	23	227.70
16/03/2022	6	500	5,000.00	11	1,977	19,849.08
17/03/2022	8	1,000	10,100.00	7	1,452	14,955.60
18/03/2022	4	500	5,050.00	1	94	958.80
21/03/2022	4	1,000	10,000.00	2	407	4,192.10
22/03/2022	5	251	2,530.08	14	1,999	20,409.79
23/03/2022	3	500	5,150.00	2	500	5,200.00
24/03/2022	6	500	5,100.00	-	-	-
25/03/2022	12	926	9,454.46	2	260	2,678.00
28/03/2022	4	500	5,095.00	4	548	5,638.92
29/03/2022	2	501	5,110.20	14	2,457	25,307.10
30/03/2022	3	311	3,234.40	3	495	5,148.00
31/03/2022	11	542	5,631.38	-	-	-
01/04/2022	8	1,234	12,685.52	-	-	-
04/04/2022	5	598	6,099.60	6	1,000	10,320.00
05/04/2022	1	228	2,325.60	2	500	5,150.00
06/04/2022	1	137	1,397.40	1	6	61.80
07/04/2022	3	500	5,100.00	3	170	1,751.00
08/04/2022	5	473	4,777.30	2	2	20.40
11/04/2022	1	485	4,898.50	8	998	10,179.60
12/04/2022	10	1,000	10,150.00	3	867	8,886.75
13/04/2022	17	1,599	15,910.05	-	-	-
14/04/2022	17	1,500	14,655.00	1	100	990.00
19/04/2022	-	-	-	2	500	4,900.00
20/04/2022	1	1	9.70	20	1,500	14,850.00
21/04/2022	2	6	59.28	6	500	5,000.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	**993**	**152,845**	**1,470,441.72**	**636**	**98,168**	**1,025,659.18**
22/04/2022	5	495	4,900.50	-	-	-
25/04/2022	20	1,782	17,231.94	1	7	69.30
26/04/2022	11	2,401	22,425.34	-	-	-
27/04/2022	6	2,005	17,984.85	-	-	-
28/04/2022	1	20	180.00	8	1,250	11,400.00
29/04/2022	-	-	-	7	2,000	18,500.00
02/05/2022	4	500	4,600.00	11	550	5,120.50
03/05/2022	3	150	1,392.00	-	-	-
05/05/2022	2	102	938.40	1	450	4,230.00
06/05/2022	6	898	8,315.48	-	-	-
09/05/2022	14	1,980	17,919.00	-	-	-
11/05/2022	10	2,544	22,387.20	9	1,316	11,962.44
12/05/2022	10	1,207	10,452.62	-	-	-
13/05/2022	6	678	5,810.46	2	802	7,009.48
16/05/2022	8	1,291	10,973.50	-	-	-
17/05/2022	4	1,012	8,551.40	7	1,500	12,900.00
18/05/2022	-	-	-	9	1,131	10,031.97
19/05/2022	-	-	-	5	619	5,614.33
20/05/2022	2	251	2,233.90	3	500	4,500.00
23/05/2022	3	1,499	13,341.10	4	250	2,262.50
24/05/2022	4	275	2,420.00	1	500	4,450.00
25/05/2022	-	-	-	2	400	3,560.00
26/05/2022	1	500	4,450.00	3	500	4,500.00
27/05/2022	16	2,488	21,645.60	-	-	-
30/05/2022	3	1,000	8,550.00	1	1	8.80
31/05/2022	7	750	6,435.00	3	849	7,386.30
01/06/2022	-	-	-	4	500	4,300.00
02/06/2022	9	500	4,300.00	2	152	1,322.40
03/06/2022	15	1,200	10,224.00	2	149	1,296.30
06/06/2022	3	600	5,100.00	1	1	8.60
07/06/2022	1	1	8.51	3	189	1,625.40
08/06/2022	4	150	1,282.50	4	411	3,538.71
09/06/2022	3	655	5,619.90	-	-	-
10/06/2022	8	845	7,233.20	3	500	4,350.00
13/06/2022	21	2,488	20,501.12	-	-	-
14/06/2022	21	4,100	32,267.00	-	-	-
15/06/2022	5	1,500	11,220.00	-	-	-
16/06/2022	10	3,000	21,540.00	-	-	-

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	**993**	**152,845**	**1,470,441.72**	**636**	**98,168**	**1,025,659.18**
17/06/2022	3	1,000	7,000.00	1	500	3,600.00
20/06/2022	7	1,000	7,000.00	3	971	6,942.65
21/06/2022	1	500	3,550.00	3	180	1,299.60
22/06/2022	16	4,500	30,375.00	1	500	3,500.00
23/06/2022	8	1,000	6,650.00	-	-	-
24/06/2022	-	-	-	5	500	3,350.00
27/06/2022	10	2,000	12,960.00	4	500	3,400.00
28/06/2022	7	2,500	15,325.00	1	1	6.50
29/06/2022	18	6,000	34,260.00	1	500	2,950.00
30/06/2022	-	-	-	1	4	22.80

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs
media@inventivapharma.com
+1 240 620 9175

Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux / Matthieu Benoist
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284

Important Notice

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including recruitment, screening and enrolment for those trials, including LEGEND, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, including LEGEND, the potential therapeutic benefits of lanifibranor in combination with empagliflozin, the design of trials, including LEGEND, pipeline and preclinical and clinical development plans, milestone payments, royalties and product sales, future activities, expectations, plans, growth and prospects of Inventiva and the sufficiency of Inventiva's cash resources and cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", "plans", "designed", "hopefully" and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine and related impacts and potential impacts

on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated timelines. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.

All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.